Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea
- 1Vaccines and Immunity Theme, Medical Research Council Unit the Gambia at London School of Hygiene and Tropical Medicine, Fajara, Gambia
- 2Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States
- 3CIH LMU Center for International Health, Medical Center of the University of Munich (LMU), Munich, Germany
- 4The Vaccine Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom
- 5Harvard Medical School, Boston, MA, United States
- 6PROOF Centre of Excellence, Vancouver, BC, Canada
- 7Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada
- 8Division of Medicine Critical Care, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
- 9Department of Cardiology, Boston Children's Hospital, Boston, MA, United States
- 10Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia
- 11Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- 12BC Cancer Agency, Vancouver, BC, Canada
- 13Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
- 14Department of Pathology, Boston Children's Hospital, Boston, MA, United States
- 15Department of Microbiology & Immunology, University of British Columbia, Vancouver, BC, Canada
- 16Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada
- 17Division of Respiratory Medicine, Department of Medicine, UBC, Vancouver, BC, Canada
- 18Division of Pediatrics, School of Medicine, Perth Children's Hospital, University of Western Australia, Nedlands, WA, Australia
- 19Broad Institute of MIT & Harvard, Cambridge, MA, United States
by Idoko, O. T., Smolen, K. K., Wariri, O., Imam, A., Shannon, C. P., Dibassey, T., et al. (2020). Front. Pediatr. 8:197. doi: 10.3389/fped.2020.00197
In the original article, there was an omission in the legend for Figure 2 as published. “FW” in the figure stands for Field worker. The correct legend appears below.
Figure 2 ∣ Field algorithm for management of intercurrent illness during the EPIC-002 study. Green, amber and red signs are as defined in Supplementary Table 2. FW, Field worker.
In the original article, there was a mistake in Table 1 as published. Column headings below groups 4, 5, and 6 should read BCG and not HepB. The corrected Table 1 appears above.
Table 1. Clinical cohort table for infants recruited in The Gambia (discovery cohort) and Papua New Guinea (validation cohort).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: markers, newborn, vaccine, immunogenicity, systems biology, OMICS
Citation: Idoko OT, Smolen KK, Wariri O, Imam A, Shannon CP, Dibassey T, Diray-Arce J, Darboe A, Strandmark J, Ben-Othman R, Odumade OA, McEnaney K, Amenyogbe N, Pomat WS, van Haren S, Sanchez-Schmitz G, Brinkman RR, Steen H, Hancock REW, Tebbutt SJ, Richmond PC, van den Biggelaar AHJ, Kollmann TR, Levy O, Ozonoff A and Kampmann B (2020) Corrigendum: Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea. Front. Pediatr. 8:610461. doi: 10.3389/fped.2020.610461
Received: 25 September 2020; Accepted: 28 September 2020;
Published: 17 November 2020.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2020 Idoko, Smolen, Wariri, Imam, Shannon, Dibassey, Diray-Arce, Darboe, Strandmark, Ben-Othman, Odumade, McEnaney, Amenyogbe, Pomat, van Haren, Sanchez-Schmitz, Brinkman, Steen, Hancock, Tebbutt, Richmond, van den Biggelaar, Kollmann, Levy, Ozonoff and Kampmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Olubukola T. Idoko, YnVra3lpZG9rbyYjeDAwMDQwO2dtYWlsLmNvbQ==; T2x1YnVrb2xhLklkb2tvJiN4MDAwNDA7bHNodG0uYWMudWs=; Ofer Levy, b2Zlci5sZXZ5JiN4MDAwNDA7Y2hpbGRyZW5zLmhhcnZhcmQuZWR1; Beate Kampmann, YmthbXBtYW5uJiN4MDAwNDA7bXJjLmdt
†These authors have contributed equally to this work and shares senior authorship